Welcome to our dedicated page for Regencell Bioscience Holdings SEC filings (Ticker: RGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
we are an early-stage bioscience company that focuses on research, development and commercialization of tcm for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder (“adhd”), autism spectrum disorder (“asd”) in infectious diseases such as covid-19. our goal is to improve the lives of adhd, asd and covid patients, their families and caregivers and become a market leader for the best tcm treatment globally.Regencell Bioscience Holdings (RGC) filed its annual Form 20‑F, outlining an early‑stage TCM bioscience business focused on ADHD and ASD with no approved products and continued losses. The company reported net losses of $3.58 million for fiscal 2025 and $4.36 million for 2024, reflecting ongoing R&D and administrative spend. As of June 30, 2025, 494,488,908 ordinary shares were outstanding.
On June 13, 2025, RGC executed a 38‑for‑1 forward stock split by capitalizing its share premium, issuing additional shares with no cash outflow and no change to authorized capital or par value. The auditor included a going concern explanatory paragraph, citing recurring losses and funding needs. Management also disclosed material weaknesses in internal controls over financial reporting, including limited U.S. GAAP/SEC reporting expertise, absence of an internal audit function, and segregation‑of‑duties gaps. The filing highlights substantial execution, regulatory and commercialization risks, and notes recent extreme share‑price volatility unrelated to operating changes.
FAQ
What is the current stock price of Regencell Bioscience Holdings (RGC)?
What is the market cap of Regencell Bioscience Holdings (RGC)?
